Business Wire

UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...
Healio

Safety of TV-46000, long-acting injection for schizophrenia, consistent in phase 3 study

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Rates of adverse events were similar in both dosing ...
Monthly Prescribing Reference

Application for Long-Acting Schizophrenia Treatment Accepted for Review

Syringe and Vials Patients treated with the investigational subcutaneous risperidone injection experienced a statistically significant delay in the time to relapse. The Food and Drug Administration ...
Business Wire

Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia

TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the ...
Medscape

Long-Acting Risperidone Injection

Purpose: The pharmacology, pharmaceutics, clinical efficacy, adverse effects, cost, and dosage and administration of long-acting risperidone injection are reviewed. Summary: Risperidone is the first ...
Healio

FDA approves long-acting injection for schizophrenia

Please provide your email address to receive an email when new articles are posted on . The FDA approved a long-acting subcutaneous risperidone injection for the treatment of schizophrenia in adults.